Evidence for an association between the SRD5A2 (type II steroid 5 alpha-reductase) locus and prostate cancer in Italian patients

Dis Markers. 2000;16(3-4):147-50. doi: 10.1155/2000/683607.

Abstract

We have investigated the contributions of three polymorphic markers in the SRD5A2 gene to prostate cancer in a group of Italian patients. We have genotyped cases and controls for a polymorphic (TA)n dinucleotide repeat and two functional substitutions, A49T and V89L, substituting respectively alanine with threonine at codon 49, and valine to leucine at codon 89. We found a substantially increased but not significant risk associated with the 49T mutation and a reduction of risk for the V89L substitution. In conclusion, we report on preliminary evidence for both increased and decreased risk associated with separate markers at this locus.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 3-Oxo-5-alpha-Steroid 4-Dehydrogenase / genetics*
  • Adenocarcinoma / enzymology
  • Adenocarcinoma / genetics*
  • Aged
  • Aged, 80 and over
  • Amino Acid Substitution
  • Androstane-3,17-diol / analogs & derivatives
  • Androstane-3,17-diol / blood
  • Codon / genetics
  • Dinucleotide Repeats
  • Ethnicity / genetics
  • Gene Frequency
  • Genetic Markers
  • Genetic Predisposition to Disease
  • Genotype
  • Humans
  • Italy / epidemiology
  • Male
  • Middle Aged
  • Mutation, Missense
  • Neoplasm Proteins / genetics
  • Polymorphism, Genetic
  • Prostatic Neoplasms / enzymology
  • Prostatic Neoplasms / genetics*
  • Risk

Substances

  • Codon
  • Genetic Markers
  • Neoplasm Proteins
  • Androstane-3,17-diol
  • androstane-3,17-diol glucuronide
  • 3-Oxo-5-alpha-Steroid 4-Dehydrogenase